C14ORF166 overexpression is associated with pelvic lymph node metastasis and poor prognosis in uterine cervical cancer

Tumor Biology

Volumn 37, Issue 1, 2016, Pages 369-379

  Zhang, Weijing ^a   Ou, Jianping ^b   Lei, Fangyong ^c   Hou, Teng ^d   Wu, Shu ^c   Niu, Chunhao ^a   Xu, Liqun ^e   Zhang, Yanna ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e Guangdong Women and Children Hospital   (China)

Author keywords

Biomarker; C14ORF166; Cervical cancer; Lymph node metastasis; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; SQUAMOUS CELL CARCINOMA ANTIGEN; C14ORF166 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER TISSUE; CERVICAL CANCER CELL LINE; CHROMOSOME 14; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GYNECOLOGIC SURGERY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OPEN READING FRAME; OVERALL SURVIVAL; PELVIS LYMPH NODE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT PLANNING; UTERINE CERVIX CANCER; VITAL SIGN; WESTERN BLOTTING; AGED; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS;

AGED; BIOMARKERS, TUMOR; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; OPEN READING FRAMES; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; UTERINE CERVICAL NEOPLASMS;

EID: 84938152372     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3806-3     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. 2012. CA Cancer J Clin. 2012;62:10–29.
2. de Guadalupe C-LM, Hernández-Gallegos E, Vázquez-Sánchez AY, Gariglio P, Camacho J. Antiproliferative and proapoptotic effects of astemizole on cervical cancer cells. Int J Gynecol Cancer. 2014;24:824–8.
3. Shin HJ, Joo J, Yoon JH, Yoo CW, Kim JY. Physical status of human papillomavirus integration in cervical cancer is associated with treatment outcome of the patients treated with radiotherapy. PLoS One. 2014;9, e78995.
4. Jiménez-Wences H, Peralta-Zaragoza O, Fernández-Tilapa G. Human papilloma virus, DNA methylation and microRNA expression in cervical cancer. Oncol Rep. 2014;31:2467–76.
5. Gadducci A, Guerrieri ME, Greco C. Tissue biomarkers as prognostic variables of cervical cancer. Crit Rev Oncol Hematol. 2013;86:104–29.
6. Wang J, Gu Y, Wang L, Hang X, Gao Y, Wang H, et al. HUPO BPP pilot study: a proteomics analysis of the mouse brain of different developmental stages. Proteomics. 2007;7:4008–15.
7. NCCN. NCCN clinical practice guidelines in oncology-cervical cancer. 2011; V1 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (17 May 2011,date last accessed).
8. Huarte M, Sanz-Ezquerro JJ, Roncal F, Ortín J, Nieto A. PA subunit from influenza virus polymerase complex interacts with a cellular protein with homology to a family of transcriptional activators. J Virol. 2001;75:8597–604.
9. Pérez-González A, Pazo A, Navajas R, Ciordia S, Rodriguez-Frandsen A, Nieto A. hCLE/C14orf166 associates with DDX1-HSPC117-FAM98B in a novel transcription-dependent shuttling RNA-transporting complex. PLoS One. 2014;9, e90957.
10. Wang J, Gu Y, Wang L, et al. HUPO BPP pilot study: a proteomics analysis of the mouse brain of different developmental stages. Proteomics. 2007;7:4008–15.
11. Guo J, Wang W, Liao P, et al. Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci. 2009;100:2292–301.
12. Cui Y, Wu J, Zong M, et al. Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer. 2009;124:1614–21.
13. Chen X, Ying Z, Lin X, et al. Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest. 2013;123:2576–89.
14. Hu Y, Chen H, Duan C, et al. Deficiency of Erbin induces resistance of cervical cancer cells to anoikis in a STAT3-dependent manner. Oncogenesis. 2013;2, e52.
15. Siejka A, Schally AV, Barabutis N. Activation of Janus kinase/signal transducer and activator of transcription 3 pathway by growth hormone-releasing hormone. Cell Mol Life Sci. 2010;67:959–64.
16. Sturgeon CM, Duffy MJ, Hofmann BR, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010;56:e1–48.
17. Juang CM, Wang PH, Yen MS, Lai CR, Ng HT, Yuan CC. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 2000;76:103–6.
18. Gaarenstroom KN, Kenter GG, Bonfrer JM, et al. Can initial serum cyfra 21–1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? Gynecol Oncol. 2000;77:164–70.
19. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809.
20. Yu H, Jove R. The STATs of cancer—new molecular targets come of age. Nat Rev Cancer. 2004;4:97–105.
21. Zhang ZH, Yu LJ, Hui XC, et al. Hydroxy-safflor yellow A attenuates Aβ1-42-induced inflammation by modulating the JAK2/STAT3/NF-κB pathway. Brain Res. 2014;1563:72–80.
22. Saravanan S, Hairul Islam VI, Prakash Babu N, et al. Swertiamarin attenuates inflammation mediators via modulating NF-κB/I κB and JAK2/STAT3 transcription factors in adjuvant induced arthritis. Eur J Pharm Sci. 2014;56:70–86.
23. Zeng KW, Wang S, Dong X, Jiang Y, Jin HW, Tu PF. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events. Toxicol Appl Pharmacol. 2014;275:244–56.
24. Zeng KW, Wang S, Dong X, Jiang Y, Tu PF. Sesquiterpene dimer (DSF-52) from Artemisia argyi inhibits microglia-mediated neuroinflammation via suppression of NF-κB, JNK/p38 MAPKs and Jak2/Stat3 signaling pathways. Phytomedicine. 2014;21:298–306.
25. Deivendran S, Marzook KH, Radhakrishna PM. The role of inflammation in cervical cancer. Adv Exp Med Biol. 2014;816:377–99.
26. Parida S, Mandal M. Inflammation induced by human papillomavirus in cervical cancer and its implication in prevention. Eur J Cancer Prev. April 2014.
27. Sobti RC, Singh N, Hussain S, Suri V, Bharti AC, Das BC. Overexpression of STAT3 in HPV-mediated cervical cancer in a north Indian population. Mol Cell Biochem. 2009;330:193–9.
28. Geirsson RT. Progesterone and an aftermath to FIGO2009. Acta Obstet Gynecol Scand. 2009;88:1178–9.
29. Zhang L, Huang H, Zhang L, et al. URG4 overexpression is correlated with cervical cancer progression and poor prognosis in patients with early-stage cervical cancer. BMC Cancer. 2014;14:885.
30. Wang W, Jia HL, Huang JM, et al. Identification of biomarkers for lymph node metastasis in early-stage cervical cancer by tissue-based proteomics. Br J Cancer. 2014;110:1748–58.
31. Noordhuis MG, Fehrmann RS, Wisman GB, et al. Involvement of the TGF-beta and betacatenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res. 2011;17:1317–30.
32. Li Z, Yu CP, Zhong Y, et al. Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer. Ann Oncol. 2012;23:638–46.
33. Jeong BK, Huh SJ, Choi DH, Park W, Bae DS, Kim BG. Prognostic value of different patterns of squamous cell carcinoma antigen level for the recurrent cervical cancer. Cancer Res Treat. 2013;45:48–54.
34. Jeong BK, Choi DH, Huh SJ, Park W, Bae DS, Kim BG. The role of squamous cell carcinoma antigen as a prognostic and predictive factor in carcinoma of uterine cervix. Radiat Oncol J. 2011;29:191–8.
35. Pang X, Zhang Y, Wei H, et al. Expression and effects of high-mobility group box 1 in cervical cancer. Int J Mol Sci. 2014;15:8699–712.
36. Lee YY, Choi CH, Sung CO, et al. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol. 2012;124:92–7.
37. Li J, Chen P, Mao CM, Tang XP, Zhu LR. Evaluation of diagnostic value of four tumor markers in bronchoalveolar lavage fluid of peripheral lung cancer. Asia Pac J Clin Oncol. 2014;10:141–8.
38. Cao X, Zhang L, Feng GR, et al. Preoperative Cyfra21-1 and SCC-Ag serum titers predict survival in patients with stage II esophageal squamous cell carcinoma. J Transl Med. 2012;10:197–203.
39. Deng Z, Hasegawa M, Yamashita Y, et al. Prognostic value of human papillomavirus and squamous cell carcinoma antigen in head and neck squamous cell carcinoma. Cancer Sci. 2012;103:2127–34.
40. Torre GC. SCC antigen in malignant and nonmalignant squamous lesions. Tumour Biol. 1998;19:517–26.
41. Kim YT, Yoon BS, Kim JW, Kim SH, Kwon JY, Kim JH. Pretreatment levels of serum squamous cell carcinoma antigen and urine polyamines in women with squamous cell carcinoma of the cervix. Int J Gynaecol Obstet. 2005;91:47–52.
42. Takeda M, Sakuragi N, Okamoto K, et al. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet Gynecol Scand. 2002;81:451–7.
43. Gaarenstroom KN, Bonfrer JM, Korse CM, Kenter GG, Kenemans P. Value of Cyfra 21–1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer. Anticancer Res. 1997;17:2955–8.
44. Chen J, Yao D, Li Y, et al. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med. 2013;32:557–67.
45. Sturgeon CM, Duffy MJ, Hofmann BR, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010;56:e1–48.